Раздел 5.6

1. Osteosarcoma: current treatment and a collaborative pathway to success / M.S. Isakoff, S.S. Bielack, P. Meltzer // Journal of clinical oncology. — 2015. — 33. — 27. — P.3029-3035
2. Результаты комбинированного лечения детей и подростков с остеосаркомой / Ю.А. Пунанов, Т.В. Андреева, Г.И. Гафтон // Онкопедиатрия. 2014. 2. С.49-53.
3. Sarcoma classification: An update based on the 2013 World health organization classification of tumors of soft tissue and bone / L.A. Doyle // Cancer. 2014. 120. P.1763–1774.
4. Pathology and Genetics of Tumours of Soft Tissue and Bone / C.D.M. Fletcher, J.A. Bridge, J.A. Hogendoorn // WHO classification 2013. http:/sarcomahelp.org/reviews/who-classification-sarcomas.html.
5. Osteosarcoma studies at St. Jude Children’s research hospital from 1968 through 1990 / C.B. Pratt, W.H. Meyer, B.N. Rao // Cancer treatment and research. 1993. 62. P. 323-326.
6. Adjuvant chemotherapy with six drugs (Adriamycin, methotrexate, cisplatinum, bleomycin, cyclophosphamide and dactinomycin) for non-metastatic high grade osteosarcoma of the extremities. Results of 32 patients and comparison to 127 patients concomitantly treated with the same drugs in a neoadjuvant form / M. Avella, G. Bacci, D.J. McDonald // Chemioterapia. 1988. 7. 2. P. 133-137.
7. Long-term results of the co-operative German-Austrian-Swiss osteosarcoma study group’s protocol COSS-86 of intensive multidrug chemotherapy and surgery for osteosarcoma of the limbs / N. Fuchs, S.S. Bielack, D. Epler // Annals of oncology. 1998. 9. P. 893-899.
8. Chemotherapy for non-metastatic high-grade osteosarcoma of extremity — is neoadjuvant better than adjuvant? / RKC. Ngan // Hong Kong journal of radiology. 2003. 6. P. 7-14.
9. Mechanisms of therapy resistance in osteosarcoma: a review / J. PosthumaDeBoer, B.J. vanRoyen, M.N. Helder // Oncology discovery. 2013. http://www.hoajonline.com/journals/pdf/2052-6199-1-8.pdf.
10. Gemcitabine and docetaxel for the treatment of children and adolescents with recurrent or refractory osteosarcoma: Korea Cancer Center Hospital experience / B.S. Song, J. Seo, D.H. Kim // Pediatric blood cancer. 2014. 61. 8. P. 1376-1381.
11. Neoadjuvant Chemotherapy With High-Dose Ifosfamide, High-Dose Methotrexate, Cisplatin, and Doxorubicin for Patients With Localized Osteosarcoma of the Extremity: A Joint Study by the Italian and Scandinavian Sarcoma Groups / S. Ferrari, S. Smeland, M.Mercuri // Journal of clinical oncology. 2005. 23. 34. P. 8845-8852.
12. Neoadjuvant Chemotherapy With Methotrexate, Cisplatin, and Doxorubicin With or Without Ifosfamide in Nonmetastatic Osteosarcoma of the Extremity: An Italian Sarcoma Group Trial ISG/OS-1 / S. Ferrari, P. Ruqqieri, G. Cefalo // Journal of clinical oncology. 2012. 30. 17. P. 2112-2118.
13. Nonmetastatic osteosarcoma of the extremity. Neoadjuvant chemotherapy with methotrexate, cisplatin, doxorubicin and ifosfamide. An Italian sarcoma group (ISG/OS-oss) / S. Ferrari, C. Meazza, E. Palmerini // Tumori. 2014. 100. P.612 618.
14. A randomised trial comparing preoperative high-dose methotrexate plus doxorubicin to high-dose methotrexate plus etoposide and ifosfamide in osteosarcoma patients / M.C. Le Deley, J.M. Guinebretiere, V.C. Gentet // European journal of cancer. 2007. 43. P.752-761.
15. Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: a pediatric oncology group trial. / A.M. Goorin, M.B. Harris, M. Bernstein // Journal of clinical oncology. 2002. 2. P. 426-433.
16. High-Dose Chemotherapy with Stem Cell Rescue in the Primary Treatment of Metastatic and Pelvic Osteosarcoma: Final Results of the ISG/SSG II Study / K. Boye, A.B. Del Prever, E. Eiksson // Pediatric blood cancer. 2014. 61. 5. P. 840-845.
17. Comparison of MAPIE versus MAP in patients with poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS1): an open-label, international, randomized controlled trial / N.M. Marina, S.Smeland, S.S. Bielack // Lancet oncology. 2016. 17. 10. P. 1396-1408.
18. Relationship between hypermetylated MGMT gene and osteosarcoma necrosis rate after chemotherapy / Q. Cui, W. Jiang, J. Guo // Pathology oncology research. 2011. 17. P. 587-591.
19. The significance of MGMT protein detection in evaluation of osteosarcoma necrosis rate after cisplatin chemotherapy / Q. Cui, D. Li, C. Liu // Bosnian journal of basic medical sciences. 2011. 11. 2. P. 80-83.
20. ERCC1 protein expression predicts survival in patients with high-grade, non-metastatic osteosarcoma treated with neoadjuvant chemotherapy / C.M. Hattinger, F. Michelacci, F. Sella // Histopathology. 2015. 67. 3. P. 338-347.
21. . Role of topoisomerases in pediatric high grade osteosarcomas: TOP2A gene is one of the unique molecular biomarkers of chemoresponse / A. Nguyen, C. Lasthaus, E. Guerin // Cancer. 2013. 5. P. 662-675.
22. Transcription factor OCT4 promotes osteosarcoma by regulating IncRNAAK055347 / H. Fan, G. Liu, C. Zhao // Oncology letters. 2017. 13. P. 396-402.
23. CD133 expression predicts lung metastases and poor prognosis in osteosarcoma patients: a clinical and experimental study / A. He, W. Qi, Y. Huang // Experimental and therapeutic medicine. 2012. 4. P. 435-441.
24. C-MYC overexpression promotes osteosarcoma cell invasion via activation of MEK-ERK pathway / G. Han, Y. Wang, W. Bi // Oncology research. 2012. 20. P. 149-156
25. Expression of HER2/erbB-2 Correlates With Survival in Osteosarcoma / R. Gorlick, A.G. Huvos, G. Heller // Journal of clinical oncology. 1999. 17. P.2781-2788.
26. Osteosarcoma / J. Ritter, S.S. Bielack // Annals of Oncology. 2010. 21. P. 320–325.
27. Autocrine VEGF/VEGFR1 signaling in a subpopulation of cell associates with aggressive osteosarcoma / T. Ohba, A.M.M. Cates, H.A. Cole // Molecular cancer research. 2014. 12. 8. P.1100-1111.
28. C-MYC overexpression promotes osteosarcoma cell invasion via activation of MEK-ERK pathway / G. Han, Y. Wang, W. Bi // Oncology research. 2012. 20. P. 149-156
29. A study of bevacizumab in combination with chemotherapy for treatment of osteosarcoma / 29 Bishop, M. https://clinicaltrials.gov/ct2/show/study/NCT00667342
30. ErbB2 Expression Is Correlated with Increased Survival of Patients with Osteosarcoma / T. Akatsuka, T. Wada, Y. Kokai // Cancer. 2002. 94. P. 1397–404.
31. HER-2 Expression is Not Prognostic in Osteosarcoma; A Children’s Oncology Group Prospective Biology Study / S. Gorlick, D.A. Barkauskas, M. Krailo // Pediatric blood cancer. 2014. 61. P. 1558-1564.
32. Phase II Trial of Trastuzumab in Combination With Cytotoxic Chemotherapy for Treatment of Metastatic Osteosarcoma With Human Epidermal Growth Factor Receptor 2 Overexpression: A Report From the Children’s Oncology Group / D. Ebb, G. Holcombe, M. Karen // Journal of clinical oncology. 2012. 30. 20. P. 2245-2551.
33. Randomised trial of two regimens of chemotherapy inoperable osteosarcoma: a study of the European Osteosarcoma Intergroup / R.L. Souhami, A.W. Craft, J.W.V. der Eijken // The Lancet. 1997. 350. P. 911-917.
34. Translational biology of osteosarcoma / M. Kansara, M.W. Teng, M.J. Smith // Nature Rewiews Cancer. 2014. P.722-735.
35. The Combination of Sorafenib and Everolimus Abrogates mTORC1 and mTORC2 Upregulation in Osteosarcoma Preclinical Models / P. Ymera, C. Dell'Aglio, M. Basiricо // Clinical Cancer Research. 2013. 19. 8. Р. 2117–31.
36. A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study / G. Grignani, E. Palmerini, P. Dileo // Annals of oncology. 2012. 23. 2. P. 508-516.
37. A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study / G. Grignani, E. Palmerini, P. Dileo // Annals of oncology. 2012. 23. 2. P. 508-516.
38. A Phase I Trial and Pharmacokinetic Study of Sorafenib in Children with Refractory Solid Tumors or Leukemias: A Children's Oncology Group Phase I Consortium Report / B.C. Wideman, A. Kim, E. Fox // Clinical Cancer Research. 2012. 18. 21. Р.6011–6022.
39. Methotrexate, doxorubicin and cisplatin (MAP) plus maintenance pegylated interferon α — 2b versus MAP alone in patients with resectable high-grade osteosarcoma and good histologic response to preoperative MAP: first results of the EURAMOS1 Good response Randomized controlled trial / S.S. Bielack, S. Smeland, J.S. Whelan // Journal of clinical oncology. 2015. 33. 20. P.2279-2287.
40. Combination of gemcitabine and docetaxel in the treatment of children and young adults with refractory bone sarcoma / F. Navid, J.R. Willert, M.B. McCarville // Cancer. 2008. 113. 2. P. 419-425.
41. Higher Gemcitabine Dose Was Associated With Better Outcome of Osteosarcoma Patients Receiving Gemcitabine-Docetaxel Chemotherapy / J.A. Lee, D.G. Jeon, W.H. Cho // Pediatric blood and cancer. 2016. 63. P.1552–1556.